PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Steve Van Wormer has published nearly 500 podcasts about pulmonary hypertension (PH) — more than perhaps anyone working in rare diseases.

Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.

Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – tiakis ...

AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...